Drugging the Schistosome Zinc-Dependent HDACs: Current Progress and Future Perspectives

References

• Brown M . Schistosomiasis. Clin. Med.11 (5), 479–482 (2011).
   PubMed Web of Science ®Google Scholar
• Ross A , BartleyP, SleighAet al. Schistosomiasis. N. Engl. J. Med.346 (16), 1212–1220 (2002).
   PubMed Web of Science ®Google Scholar
• Barsoum R . Urinary schistosomiasis: review. J. Adv. Res.4 (5), 453–459 (2013).
   PubMedGoogle Scholar
• Elbaz T , EsmatG. Hepatic and intestinal schistosomiasis: review. J. Adv. Res.4 (5), 445–452 (2013).
   PubMedGoogle Scholar
• Gray D , RossA, LiY, McmanusD. Diagnosis and management of schistosomiasis. BMJ342, d2651 (2011).
   PubMed Web of Science ®Google Scholar
• Dömling A , KhouryK. Praziquantel and Schistosomiasis. ChemMedChem5 (9), 1420–1434 (2010).
   PubMed Web of Science ®Google Scholar
• Doenhoff M , CioliD, UtzingerJ. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasisCurr. Opin. Infect. Dis.21, 659–667 (2008).
   PubMed Web of Science ®Google Scholar
• Doenhoff M , KuselJ, ColesG, CioliD. Resistance of Schistosoma mansoni to praziquantel: is there a problem?Trans. R. Soc. Trop. Med. Hyg.96 (5), 465–469 (2002).
   PubMed Web of Science ®Google Scholar
• Coeli R , BabaE, AraujoN, CoelhoP, OliveiraG. Praziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infections. PLoS Negl. Trop. Dis.7 (12), e2596 (2013).
   PubMed Web of Science ®Google Scholar
• Conaway J . Introduction to theme 'chromatin, epigenetics, and transcription'. Annu. Rev. Biochem.81 (1), 61–64 (2012).
   PubMedGoogle Scholar
• Arrowsmith C , BountraC, FishP, LeeK, SchapiraM. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Dis.11 (5), 384–400 (2012).
   PubMed Web of Science ®Google Scholar
• Luger K , MaderA, RichmondR, SargentD, RichmondT. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature389 (6648), 251–260 (1997).
   PubMed Web of Science ®Google Scholar
• Li G , ReinbergD. Chromatin higher-order structures and gene regulation. Curr. Opin. Genet. Dev.21 (2), 175–186 (2011).
   PubMed Web of Science ®Google Scholar
• Dawson M , KouzaridesT. Cancer epigenetics: from mechanism to therapy. Cell150 (1), 12–27 (2012).
   PubMed Web of Science ®Google Scholar
• Chen T , DentS. Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat. Rev. Genet.15 (2), 93–106 (2014).
   PubMed Web of Science ®Google Scholar
• Margueron R , ReinbergD. Chromatin structure and the inheritance of epigenetic information. Nat. Rev. Genet.11 (4), 285–296 (2010).
   PubMed Web of Science ®Google Scholar
• Bannister A , KouzaridesT. Regulation of chromatin by histone modifications. Cell Res.21 (3), 381–395 (2011).
   PubMed Web of Science ®Google Scholar
• Kouzarides T . Chromatin modifications and their function. Cell128 (4), 693–705 (2007).
   PubMed Web of Science ®Google Scholar
• Zentner G , HenikoffS. Regulation of nucleosome dynamics by histone modifications. Nat. Struct. Mol. Biol.20 (3), 259–266 (2013).
   PubMed Web of Science ®Google Scholar
• Bernstein B , MeissnerA, LanderE. The mammalian epigenome. Cell128 (4), 669–681 (2007).
   PubMed Web of Science ®Google Scholar
• Ivanov M , BarraganI, Ingelman-SundbergM. Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol. Sci.35 (8), 384–396 (2014).
   PubMed Web of Science ®Google Scholar
• Murphy Tm , MillJ. Epigenetics in health and disease: heralding the EWAS era. Lancet383 (9933), 1952–1954 (2014).
   PubMed Web of Science ®Google Scholar
• Handel A , EbersG, RamagopalanS. Epigenetics: molecular mechanisms and implications for disease. Trends Mol. Med.16 (1), 7–16 (2010).
   PubMed Web of Science ®Google Scholar
• Gomez-Diaz E , JordaM, PeinadoM, RiveroA. Epigenetics of host-pathogen interactions: the road ahead and the road behind. PLoS Pathog.8 (11), e1003007 (2012).
   PubMed Web of Science ®Google Scholar
• Azzi A , CosseauC, GrunauC. Schistosoma mansoni: Developmental arrest of miracidia treated with histone deacetylase inhibitors. Exp. Parasitol.121 (3), 288–291 (2009).
   PubMed Web of Science ®Google Scholar
• Coleman B , SkillmanK, JiangRet al. A Plasmodium falciparum histone deacetylase regulates antigenic variation and gametocyte conversion. Cell Host Microbe16 (2), 177–186 (2014).
   PubMed Web of Science ®Google Scholar
• Marek M , KannanS, HauserAet al. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog.9 (9), e100364 (2013).
   Web of Science ®Google Scholar
• Carneiro V , De Abreu Da SilvaI, TorresEet al. Epigenetic changes modulate schistosome egg formation and are a novel target for reducing transmission of schistosomiasis. PLoS Pathog.10 (5), e1004116 (2014).
   PubMed Web of Science ®Google Scholar
• Hansen Fk , SumanadasaSdm, StenzelKet al. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. Eur. J. Med. Chem.82, 204–213 (2014).
   PubMed Web of Science ®Google Scholar
• Bougdour A , MaubonD, BaldacciPet al. Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. J. Exp. Med.206 (4), 953–966 (2009).
   PubMed Web of Science ®Google Scholar
• Malmquist N , MossT, MecheriS, ScherfA, FuchterM. Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum. Proc. Natl Acad. Sci. USA109 (41), 16708–16713 (2012).
   PubMed Web of Science ®Google Scholar
• Olsen C . Expansion of the lysine acylation landscape. Angew. Chem. Int. Ed. Engl.51 (16), 3755–3756 (2012).
   PubMed Web of Science ®Google Scholar
• Choudhary C , WeinertB, NishidaY, VerdinE, MannM. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat. Rev. Mol. Cell Biol.15 (8), 536–550 (2014).
   PubMed Web of Science ®Google Scholar
• Falkenberg K , JohnstoneR. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Dis.13 (9), 673–691 (2014).
   PubMed Web of Science ®Google Scholar
• Finley A , CopelandR. Small molecule control of chromatin remodeling. Chem. Biol.21 (9), 1196–1210 (2014).
   PubMedGoogle Scholar
• Yang X , SetoE. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene26 (37), 5310–5318 (2007).
   PubMed Web of Science ®Google Scholar
• Shahbazian M , GrunsteinM. Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem.76 (1), 75–100 (2007).
   PubMed Web of Science ®Google Scholar
• Josling G , SelvarajahS, PetterM, DuffyM. The role of bromodomain proteins in regulating gene expression. Genes3 (2), 320–343 (2012).
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P , KnappS. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Dis.13 (5), 337–356 (2014).
   PubMed Web of Science ®Google Scholar
• Gregoretti I , LeeY, GoodsonH. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol.338 (1), 17–31 (2004).
   PubMed Web of Science ®Google Scholar
• De Ruijter A , Van GennipA, CaronH, KempS, Van KuilenburgA. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J.370, 737–749 (2003).
   PubMed Web of Science ®Google Scholar
• Lombardi P , ColeK, DowlingD, ChristiansonD. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr. Opin. Struct. Biol.21 (6), 735–743 (2011).
   PubMed Web of Science ®Google Scholar
• Vannini A , VolpariC, FilocamoGet al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA101 (42), 15064–15069 (2004).
   PubMed Web of Science ®Google Scholar
• Moniot S , WeyandM, SteegbornC. Structures, substrates, and regulators of mammalian sirtuins and opportunities and challenges for drug development. Front. Pharmacol.3, 16 (2012).
   PubMed Web of Science ®Google Scholar
• Xu W , LiY, LiuC, ZhaoS. Protein lysine acetylation guards metabolic homeostasis to fight against cancer. Oncogene33 (18), 2279–2285 (2014).
   PubMed Web of Science ®Google Scholar
• Portela A , EstellerM. Epigenetic modifications and human disease. Nat. Biotechnol.28 (10), 1057–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Oger F , DuboisF, CabySet al. The class I histone deacetylases of the platyhelminth parasite Schistosoma mansoni. Biochem. Biophys. Res. Commun.377 (4), 1079–1084 (2008).
   PubMed Web of Science ®Google Scholar
• Pierce R , Dubois-AbdesselemF, LancelotJ, AndradeL, OliveiraG. Targeting schistosome histone modifying enzymes for drug development. Curr. Pharm. Des.18 (24), 3567–3578 (2012).
   PubMed Web of Science ®Google Scholar
• Dubois F , CabyS, OgerFet al. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol. Biochem. Parasitol.168 (1), 7–15 (2009).
   PubMed Web of Science ®Google Scholar
• Cabezas-Cruz A , LancelotJ, CabyS, OliveiraG, PierceR. Epigenetic control of gene function in schistosomes: a source of therapeutic targets?Front Genet5, 10.3389 (2014).
   PubMed Web of Science ®Google Scholar
• Musselman C , LalondeM, CoteJ, KutateladzeT. Perceiving the epigenetic landscape through histone readers. Nat. Struct. Mol. Biol.19 (12), 1218–1227 (2012).
   PubMed Web of Science ®Google Scholar
• Mireille J , LepesantJ, GrunauC, CosseauC. Towards an understanding of the epigenetics of schistosomes: a comparative epigenomic study. Mem. Inst. Oswaldo Cruz106 (7), 823–830 (2011).
   PubMed Web of Science ®Google Scholar
• Brunmeir R , LaggerS, SeiserC. Histone deacetylase 1 and 2-controlled embryonic development and cell differentiation. Int. J. Dev. Biol.53, 275–289 (2009).
   PubMed Web of Science ®Google Scholar
• Lahm A , PaoliniC, PallaoroMet al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl Acad. Sci. USA104 (44), 17335–17340 (2007).
   PubMed Web of Science ®Google Scholar
• Lancelot J , CabyS, Dubois-AbdesselemFet al. Schistosoma mansoni Sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl. Trop. Dis.7 (9), e2428 (2013).
   PubMed Web of Science ®Google Scholar
• Schiedel M , MarekM, LancelotJet al. Fluorescence-based screening assays for the NAD+-dependent histone deacetylase smSirt2 from Schistosoma mansoni. J. Biomol. Screen.20 (1), 112–121 (2014).
   PubMedGoogle Scholar
• West A , JohnstoneR. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest.124 (1), 30–39 (2014).
   PubMed Web of Science ®Google Scholar
• Feng W , ZhangB, CaiD, ZouX. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Lett.347 (2), 183–190 (2014).
   PubMed Web of Science ®Google Scholar
• Khan O , La ThangueN. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol.90 (1), 85–94 (2012).
   PubMed Web of Science ®Google Scholar
• Campbell R , TumminoP. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J. Clin. Invest.124 (1), 64–69 (2014).
   PubMed Web of Science ®Google Scholar
• Oliveira G . Cancer and parasitic infections: similarities and opportunities for the development of new control tools. Rev. Soc. Bras. Med. Trop.47, 1–2 (2014).
   PubMed Web of Science ®Google Scholar
• Nakagawa M , OdaY, EguchiTet al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep.18 (4), 769–774 (2007).
   PubMed Web of Science ®Google Scholar
• Deardorff M , BandoM, NakatoRet al. HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature489 (7415), 313–317 (2012).
   PubMed Web of Science ®Google Scholar
• Olson D , UdeshiN, WolfsonNet al. An unbiased approach to identify endogenous substrates of ‘histone’ deacetylase 8. ACS Chem. Biol.9 (10), 2210–2216 (2014).
   PubMed Web of Science ®Google Scholar
• Stolfa D , MarekM, LancelotJet al. Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen Schistosoma mansoni. J. Mol. Biol.426 (20), 3442–3453 (2014).
   PubMed Web of Science ®Google Scholar
• Dissous C , GreveldingC. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective?Trends Parasitol.27 (2), 59–66 (2011).
   PubMed Web of Science ®Google Scholar
• Schöffski P . Polo-Like Kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist14 (6), 559–570 (2009).
   PubMed Web of Science ®Google Scholar
• Long T , CailliauK, BeckmannSet al. Schistosoma mansoni Polo-like kinase 1: a mitotic kinase with key functions in parasite reproduction. Int. J. Parasitol.40 (9), 1075–1086 (2010).
   PubMed Web of Science ®Google Scholar
• Mcdermott J , JimenoA. Belinostat for the treatment of peripheral T-cell lymphomas. Drugs Today50 (5), 337–345 (2014).
   PubMed Web of Science ®Google Scholar
• Kannan S , MelesinaJ, HauserAet al. Discovery of inhibitors of Schistosoma mansoni HDAC8 by combining homology modeling, virtual screening, and in vitro validation. J. Chem. Inf. Model.54 (10), 3005–3019 (2014).
   PubMed Web of Science ®Google Scholar
• Millard C , WatsonP, CelardoIet al. Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol. Cell51 (1), 57–67 (2013).
   PubMed Web of Science ®Google Scholar
• Watson P , FairallL, SantosG, SchwabeJ. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature481 (7381), 335–340 (2012).
   PubMed Web of Science ®Google Scholar
• Lauffer B , MintzerR, FongRet al. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J. Biol. Chem.288 (37), 26926–26943 (2013).
   PubMed Web of Science ®Google Scholar
• Bottomley M , Lo SurdoP, Di GiovinePet al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem.283 (39), 26694–26704 (2008).
   PubMed Web of Science ®Google Scholar
• Schuetz A , MinJ, Allali-HassaniAet al. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem.283 (17), 11355–11363 (2008).
   PubMed Web of Science ®Google Scholar
• Tang G , WongJ, ZhangWet al. Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors. J. Med. Chem.57 (19), 8026–8034 (2014).
   PubMed Web of Science ®Google Scholar
• Balasubramanian S , RamosJ, LuoW, SirisawadM, VernerE, BuggyJj. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia22 (5), 1026–1034 (2008).
   PubMed Web of Science ®Google Scholar
• Suzuki T , MutoN, BandoMet al. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors. ChemMedChem9 (3), 657–664 (2014).
   PubMed Web of Science ®Google Scholar
• Hu J , Van Den SteenP, SangQ, OpdenakkerG. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Dis.6 (6), 480–498 (2007).
   PubMed Web of Science ®Google Scholar
• Sung Y , LeeT, YoonHet al. Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp. Neurol.239, 192–201 (2013).
   PubMed Web of Science ®Google Scholar
• Cole K , DowlingD, BooneM, PhillipsA, ChristiansonD. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J. Am. Chem. Soc.133 (32), 12474–12477 (2012).
   Web of Science ®Google Scholar
• Singh R , SuzukiT, MandalTet al. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme. Biochemistry53 (48), 7445–7458 (2014).
   PubMed Web of Science ®Google Scholar
• Somoza J , SkeneR, KatzBet al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure12 (7), 1325–1334 (2004).
   PubMed Web of Science ®Google Scholar
• Kunze M , WrightD, WerbeckN, KirkpatrickJ, CoveneyP, HansenD. Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8. J. Am. Chem. Soc.135 (47), 17862–17868 (2013).
   PubMed Web of Science ®Google Scholar
• Vennervald B , PolmanK. Helminths and malignancy. Parasite Immunol.31 (11), 686–696 (2009).
   PubMed Web of Science ®Google Scholar
• Tsai I , ZarowieckiM, HolroydNet al. The genomes of four tapeworm species reveal adaptations to parasitism. Nature496 (7443), 57–63 (2013).
   PubMed Web of Science ®Google Scholar
• Lane A , ChabnerB. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol.10 (27), 5459–5468 (2009).
   Google Scholar
• Abdulla M , RuelasD, WolffBet al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl. Trop. Dis.3 (7), e478 (2009).
   PubMed Web of Science ®Google Scholar